There was a greater incidence of hypotension-associated adverse events, some serious, including dizziness, in patients treated with FILSPARI compared to irbesartan. In patients at risk for hypotension ...

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research Co-ordinator category. As a Clinical Research Co-ordinator (CRC) you play an important role ...

Rina-S achieved a 50% confirmed objective response rate (ORR) as a monotherapy. Helena Nechaeva via Shutterstock. Genmab’s antibody drug conjugate (ADC) rinatabart sesutecan (Rina-S) demonstrated ...

Basel, June 2, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, has announced that WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are ...

Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, ...

Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10. ...

Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension . Ferdinando C. Sasso, MD, PHD, Ornella Carbonara, MD, ...

Sandoz noted that Wyost and Jubbonti are the first and only interchangeable Food and Drug Administration (FDA)-approved denosumab biosimilars and are approved to treat all indications of the reference ...

Keren Haruvi, president of Sandoz’ North America division, commented on the significance of this launch. "Denosumab is a vital medicine for conditions such as osteoporosis and cancer-related skeletal ...

Evidence also suggests that sparsentan is better at maintaining kidney function than irbesartan, but this was uncertain, NICE explained. PROTECT Study Results The regulator’s recommendation was ...